Related references
Note: Only part of the references are listed.Financial considerations in expanded access policy for gene therapies: A tough nut to crack?
B. Tobias Polak et al.
MOLECULAR THERAPY (2021)
Implementation of 21st Century Cures Act Expanded Access Policies Requirements
Sukhun Kang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Expanded Access as a source of real-world data: An overview of FDA and EMA approvals
Tobias B. Polak et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs
Ori Rozenberg et al.
AMERICAN JOURNAL OF BIOETHICS (2020)
PNS266 Collecting EARLY Access Real World Evidence DATA for a Successful Reimbursement Appraisal
L. Villemur et al.
VALUE IN HEALTH (2020)
Response to Open Peer Commentary Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs
Tobias B. Polak et al.
AMERICAN JOURNAL OF BIOETHICS (2020)
Differences Between Randomized Clinical Trial Participants and Real-World Empagliflozin Users and the Changes in Their Glycated Hemoglobin Levels
Nicolai E. Munk et al.
JAMA NETWORK OPEN (2020)
What compassionate use means for gene therapies
Carolyn Riley Chapman et al.
NATURE BIOTECHNOLOGY (2019)
What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands
Eline M. Bunnik et al.
BMC MEDICAL ETHICS (2019)
Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs
Eline M. Bunnik et al.
HEALTH POLICY (2018)
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure A Secondary Analysis of the PARADIGM-HF Trial
Alvin Chandra et al.
JAMA CARDIOLOGY (2018)
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry
Hans M. Westgeest et al.
EUROPEAN UROLOGY FOCUS (2018)
Pre-approval Access Terminology: A Cause for Confusion and a Danger to Patients
Laura L. Kimberly et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2017)
A Global, Neutral Platform for Sharing Trial Data
Barbara E. Bierer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review
Deanna J. Taylor et al.
BMJ OPEN (2016)
An overview of Compassionate Use Programs in the European Union member states
Gayathri Balasubramanian et al.
INTRACTABLE & RARE DISEASES RESEARCH (2016)
Evidence Synthesis for Decision Making 1: Introduction
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Share Paper
